Furoate glucoside analogue 1 and purpose thereof of using as alpha-glycosidase inhibitor
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of analogs and furoate, applied in the field of α-glucosidase inhibitors, can solve problems such as flatulence and diarrhea, and cumbersome synthesis steps
Inactive Publication Date: 2015-08-26
JILIN AGRICULTURAL UNIV
View PDF2 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
At present, α-glucosidase inhibitors such as acarbose and voglibose have been used as oral hypoglycemic agents in the clinical treatment of diabetes, which can effectively control postprandial blood glucose levels, but these α-glucosides After all, there are only a few enzyme inhibitors on the market, and most of them contain sugar groups, and the synthesis steps are extremely cumbersome. In addition, they have certain side effects in clinical aspects such as flatulence and diarrhea.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0023] Example 1: Preparation of α-glucosidase inhibitor furoate glycoside analog I
[0024] 1. Preparation of furoate glycoside analog I
[0025] (1) Take 500g of red ginseng, 800g of Poria cocos, 800g of Atractylodes macrocephala, 600g of astragalus, 600g of kudzu root, 1000g of sealwort, 200g of rhubarb, 200g of coptis, 400g of medlar, 200g of schisandra, and 100g of licorice, crush them, mix them well, add 50 L of water to decoct 2 times, 1 hour each time, filter and combine the filtrates;
[0026] (2) Concentrate the filtrate in step (1) to a relative density of 1.25, add 95% ethanol to make the ethanol concentration reach 60%, stand at room temperature for 18 hours, filter, collect the filtrate, evaporate the filtrate to dryness, and suspend in water;
[0027] (3) The aqueous suspension in step (2) was extracted 3 times with an equal volume of ethyl acetate, the ethyl acetate layer was discarded, and the aqueous layer was extracted with an equal volume of water-saturate...
Embodiment 2
[0057] Embodiment 2: the preparation of furoate glycoside analog I soft capsule
[0058] Take furoate glycoside analog I, suspend with soybean oil and beeswax as solvent, and make soft capsules.
Embodiment 3
[0059] Embodiment 3: the preparation of furoate glycoside analog I tablet
[0060] Take the furoate glycoside analog I, add dextrin to granulate, dry, granulate, compress into tablets, and make tablets.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention refers to the field of traditional Chinese medicine, and especially relates to furoate glucoside analogue 1 and purpose thereof of using as alpha-glycosidase inhibitor. The structure of the furoate glucoside analogue 1 is 3-(furan-2-methylcarbonyl)oxyglucopyranose aldehyde acid-1 alpha-4-D-glucopyranose-1 alpha -4-D-glucopyranose. The furoate glucoside analogue 1 has strong inhibition ability to alpha-glucosidase, and can be further developed to be drugs for treating and assisting the treatment of 2 type diabetes.
Description
technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to an alpha-glucosidase inhibitor. Background technique [0002] Diabetes mellitus (diabetes mellitus) is a chronic disease of carbohydrate, fat and protein metabolism disorder caused by relative or absolute deficiency of insulin in the body or decreased sensitivity of target cells to insulin, or structural defects of insulin itself. Its main features are hyperglycemia and diabetes. It is clinically manifested as polydipsia, polyphagia, polyuria, and weight loss (i.e. "three excesses and one less"), which can cause morphological structural changes and dysfunction in some tissues or organs, accompanied by ketoacidosis, limb gangrene, multiple Neuritis, blindness and renal failure. The disease incidence rate is increasing day by day, and has become a worldwide common disease and frequently-occurring disease. [0003] According to the Asian Diabetes Society, as of 2012, t...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more